Emmanuel Raffoux
Overview
Explore the profile of Emmanuel Raffoux including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
184
Citations
5213
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Belhadj M, Burroni B, Kosmider O, Willems L, Temple M, Bertoli S, et al.
Br J Haematol
. 2023 Jul;
202(6):e50-e53.
PMID: 37403204
No abstract available.
22.
Duployez N, Vasseur L, Kim R, Largeaud L, Passet M, LHaridon A, et al.
Leukemia
. 2023 Apr;
37(6):1245-1253.
PMID: 37085611
Tandem duplications (TDs) of the UBTF gene have been recently described as a recurrent alteration in pediatric acute myeloid leukemia (AML). Here, by screening 1946 newly diagnosed adult AML, we...
23.
Socie G, Galimard J, Raffoux E, Itzykson R, Debureaux P, Michonneau D, et al.
Haematologica
. 2023 Mar;
108(9):2369-2379.
PMID: 36951151
Debates on the role and timing of allogeneic hemtopoietic stem cell transplantation (HSCT) in acute myelogenous leukemia (AML) have persisted for decades. Time to transplant introduces an immortal time and...
24.
Vignal N, Kelly L, Lengline E, Cabannes-Hamy A, Siavellis J, Ghez D, et al.
Haematologica
. 2023 Feb;
108(9):2531-2534.
PMID: 36794507
No abstract available.
25.
Cerrano M, Chevret S, Raffoux E, Rabian F, Sebert M, Valade S, et al.
Ann Hematol
. 2023 Feb;
102(4):761-768.
PMID: 36773040
Hyperleukocytosis is associated with a significant early mortality rate in patients with acute myeloid leukemia (AML). To date, no controlled trial has ever evaluated a strategy to reduce this risk,...
26.
Sebert M, Gachet S, Leblanc T, Rousseau A, Bluteau O, Kim R, et al.
Cell Stem Cell
. 2023 Feb;
30(2):153-170.e9.
PMID: 36736290
Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical,...
27.
Bello R, Pacchiardi K, Chauvel C, Ades L, Braun T, Pasanisi J, et al.
Hemasphere
. 2022 Dec;
7(1):e819.
PMID: 36570694
No abstract available.
28.
Dumas P, Raffoux E, Berard E, Bertoli S, Hospital M, Heiblig M, et al.
Leukemia
. 2022 Nov;
37(1):91-101.
PMID: 36376378
The real-world efficacy and safety of gilteritinib was assessed in an ambispective study that included 167 R/R FLT3-mutated AML patients. Among them, 140 received gilteritinib as single agent (cohort B),...
29.
Duchmann M, Joudinaud R, Boudry A, Pasanisi J, Di Feo G, Kim R, et al.
Blood Cancer J
. 2022 Sep;
12(9):136.
PMID: 36151081
No abstract available.
30.
Fodil S, Chevret S, Rouzaud C, Valade S, Rabian F, Mariotte E, et al.
PLoS One
. 2022 Jul;
17(7):e0270744.
PMID: 35797337
Introduction: Patients with hyperleukocytic (HL) acute myeloid leukemia (AML) are at higher risk of early death. Initial management of these patients is challenging, not fully codified and heterogenous. Retrospective studies...